Clinical Trial Update: TMC125-TiDP2-C188: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Patients on Stable Buprenorphine/Naloxone Maintenance Therapy. [Phase 1]

View source ↗

Summary

Phase I open-label trial to assess pharmacokinetic interaction between TMC125 (etravirine) and buprenorphine/naloxone in HIV-negative patients on stable bupreno…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Buprenorphine/naloxone (buprenorphine/naloxone)
• etravirine (etravirine)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV, Pharmacokinetics | Phase 1 | Status: COMPLETED